Loading...

LEUKEMIA CHARACTERISATION PANEL CLPD, BLOOD

image not found

NABL Cap Accredited  
The Leukemia Characterisation Panel for Chronic Lymphoproliferative Disorders (CLPD) helps identify and classify abnormal lymphoid cells in the blood. This panel supports diagnosis, prognosis, and treatment planning for various chronic leukemias. It evaluates specific markers that distinguish different CLPD subtypes. Metropolis Healthcare performs this analysis using advanced flow cytometry for high-precision cellular profiling 

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 20,990.00

Sample Type: BLOOD

Fasting Not Required


Notes:L0097

Frequently Asked Questions (FAQ's):

What does the Leukemia Characterisation Panel CLPD include at Metropolis Healthcare?
It includes flow cytometry markers that help differentiate B-cell and T-cell lymphoproliferative disorders.

Why is this test recommended?
It assists in diagnosing chronic leukemias, monitoring disease progression, and guiding targeted therapy.

How does Metropolis Healthcare perform this test?
Highly sensitive flow cytometry is used to analyze cell-surface markers on lymphocytes.

Who should take this test?
Patients with persistent high lymphocyte counts, suspected CLPD, or unexplained lymphadenopathy.

Is a blood sample sufficient for this panel?
Yes, the test is performed on peripheral blood collected in EDTA tubes.

How accurate is CLPD characterization at Metropolis Healthcare?
The lab uses standardized panels and quality-controlled instruments for reliable immunophenotyping.

Does this panel help in treatment decisions?
Yes, identifying specific leukemia subtypes helps clinicians choose appropriate therapies.

Do medications affect test results?
Some treatments may alter lymphocyte markers; physicians should share medication history before testing

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab